Second- and third-generation drugs for immuno-oncology treatment—The more the better?

European Journal of Cancer

Volumn 74, Issue , 2017, Pages 55-72

  Dempke, Wolfram C M ^a,b   Fenchel, Klaus ^c   Uciechowski, Peter ^d   Dale, Stephen P ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Asklepios Medical School Hamburg   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Clinical development; Immuno oncology; Molecular biology; Novel antibodies

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD276 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENOBLITUZUMAB; GDC 0919; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN; GSK 3359609; INDOLEAMINEPYRROLE 2,3 DIOXYGENASE 1,2; INDOXIMOD; INDUCIBLE T CELL COSTIMULATOR; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE ACTIVATION GENE 3; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN B7; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING 3; TRX 518001; UNCLASSIFIED DRUG; UNINDEXED DRUG; UTOMILUMAB; V DOMAIN IG SUPPRESSOR OF T CELL ACTIVATION; VARLILUMAB; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD223 ANTIGEN; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; ICOS PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE; LEUKOCYTE ANTIGEN; OX40 LIGAND; TNFRSF18 PROTEIN, HUMAN; TNFRSF9 PROTEIN, HUMAN; TNFSF4 PROTEIN, HUMAN; VISTA PROTEIN, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL DEATH; CLINICAL STUDY; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE CONTROL; DRUG MECHANISM; DRUG TARGETING; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; METASTATIC MELANOMA; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; PHYSIOLOGY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; B7 ANTIGENS; CTLA-4 ANTIGEN; CYTOKINES; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; OX40 LIGAND; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, KIR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85012216757     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.001     Document Type: Review

References (82)

1. [1] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
2. [2] Sznol, M., Chen, L., Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19 (2013), 1021–1034.
3. [3] Callahan, M.K., Postow, M.A., Wolchok, J.D., CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 4 (2015), 1–6.
4. [4] Dempke, W.C.M., Sellmann, L., Fenchel, K., Immuno-oncology drugs for NSCLC: are we cutting the Gordian helix?. Anticancer Res 35 (2015), 5745–5757.
5. [5] Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
6. [6] Van Parijs, L., Abbas, A.K., Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998), 243–248.
7. [7] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2013), 252–264.
8. [8] Saito, T., Yokosuka, T., Hashimoto-Tane, A., Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett 584 (2010), 4855–4871.
9. [9] Burkholder, B., Huang, R.Y., Burgess, R., Luo, S., Jones, V.S., Zhang, W., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845 (2014), 182–201.
10. [10] Ossendorp, F., Mengedé, E., Camps, M., Filius, R., Melief, C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187 (1998), 693–702.
11. [11] Toes, R.E., Schoenberger, S.P., van der Voort, E.I., Offringa, R., Melief, C.J., CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10 (1998), 443–448.
12. [12] Quezada, S.A., Simpson, T.R., Peggs, K.S., Merghoub, T., Vider, J., Fan, X., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207 (2010), 637–650.
13. [13] Friedman, K.M., Prieto, P.A., Devillier, L.E., Gross, C.A., Yang, J.C., Wunderlich, J.R., et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 35 (2012), 400–408.
14. [14] Linnemann, C., van Buuren, M.M., Bies, L., Verdegaal, E.M., Schotte, R., Calis, J.J., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21 (2015), 81–85.
15. [15] Haabeth, O.A., Bogen, B., Corthay, A., A model for cancer-suppressive inflammation. Oncoimmunology 1 (2012), 1146–1155.
16. [16] Lettau, M., Kabelitz, D., Janssen, O., Lysosome-related effector vesicles in T lymphocytes and NK cells. Scand J Immunol 82 (2015), 235–243.
17. [17] Fehérvari, Z., Sakaguchi, S., CD4+ Tregs and immune control. J Clin Invest 114 (2004), 1209–1217.
18. [18] Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004), 942–949.
19. [19] Maddur, M.S., Bayry, J., B cells drive Th2 responses by instructing human dendritic cell maturation. Oncoimmunology, 4, 2015 e1005508-1-3.
20. [20] Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., Krysko, D.V., Immunogenic apoptotic cell death and anticancer immunity. Adv Exp Med Biol 930 (2016), 133–149.
21. [21] Kohrt, H., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123 (2014), 678–686.
22. [22] Handgretinger, R., Lang, P., André, M.C., Exploitation of natural killer cells for the treatment of acute leukemia. Blood 127 (2016), 3341–3349.
23. [23] Ceeraz, S., Nowak, E.C., Noelle, R.J., B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34 (2013), 556–563.
24. [24] Jung, K., Choi, I., Emerging co-signaling networks in T cell immune regulation. Immune Netw 5 (2013), 184–193.
25. [25] McGrath, M.M., Najafian, N., The role of coinhibitory signalling pathways in transplantation and tolerance. Front Immunol, 3, 2012, 10.3389/fimmu.2012.00047.
26. [26] Gentzler, R., Hall, R., Kunk, P.R., Gaughan, E., Dillon, P., Slingluff, C.L., et al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy 8 (2016), 583–600.
27. [27] Soria, J.C., Marabelle, A., Brahmer, J.R., Gettinger, S., Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 21 (2015), 2256–2262.
28. [28] Berman, D., Korman, A., Peck, R., Feltquate, D., Lonberg, N., Canetta, R., The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharm Ther 148 (2015), 132–153.
29. [29] Melero, I., Murillo, O., Dubrot, J., Hervas-Stubbs, S., Perez-Gracia, J.L., Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 29 (2008), 383–390.
30. [30] Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7 (2007), 95–106.
31. [31] Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M.W., Yoshizawa, H., et al. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 184 (2010), 5493–5501.
32. [32] Lin, W., Voskens, C.J., Zhang, X., Schindler, D.G., Wood, A., Burch, E., et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood 112 (2008), 699–707.
33. [33] Wilcox, R.A., Tamada, K., Strome, S.E., Chen, L., Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169 (2002), 4230–4236.
34. [34] Kohrt, H.E., Hut, R., Goldstein, M.J., Weiskopf, K., Alizadeh, A.A., Brody, J., et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117 (2011), 2423–2432.
35. [35] Fisher, T.S., Kamperschroer, C., Oliphant, T., Love, V.A., Lira, P.D., Doyonnas, R., et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 61 (2012), 1721–1733.
36. [36] Curran, M.A., Kim, M., Montalvo, W., Al-Shamkhani, A., Allison, J.P., Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6 (2011), 1–11.
37. [37] Gopal, A.K., Bartlett, N.L., Levy, R., Houot, R., Smith, S.D., Segal, N.H., et al. A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. J Clin Oncol, 33, 2015 (suppl):abstr 3004.
38. [38] Tolcher, A.W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K.P., Patnaik, A., Rasco, D.W., et al. Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol, 34, 2016 (suppl):abstr 3002.
39. [39] Fu, T., He, Q., Sharma, P., The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71 (2011), 5445–5454.
40. [40] Placke, T., Kopp, H.G., Salih, H.R., Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol, 2010, 10.1155/2010/239083.
41. [41] Hanabuchi, S., Watanabe, N., Wang, Y.H., Wang, Y.H., Ito, T., Shaw, J., et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107 (2006), 3617–3623.
42. [42] Knee, D.A., Hewes, B., Brigdon, J.L., Rationale for anti-GITR cancer immunotherapy. Eur J Cancer 67 (2016), 1–10.
43. [43] Koon, H.B., Shepard, D.R., Merghoub, T., Schaer, D.A., Sirard, C.A., Wolchok, J.D., First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. J Clin Oncol, 34, 2016 (suppl):abstr 3017.
44. [44] Nirschl, C.J., Drake, C.G., Molecular pathways: coexpression of immune checkpoint molecules: signalling pathways and implications for cancer immunotherapy. Clin Cancer Res 19 (2013), 4917–4934.
45. [45] Owonikoko, T.K., Hussain, A., Stadler, W.M., Smith, D.C., Sznol, M., Molina, A.M., et al. A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). J Clin Oncol, 32, 2014 (suppl):abstract 2558.
46. [46] Sanborn, R.E., Pishvain, M.J., Callahan, M.K., Rizvi, N., Kluger, H., Yellin, M., et al. Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. Cancer Res, 76(14 Suppl.), 2016 abstr CT023.
47. [47] So, T., Song, J., Sugie, K., Altman, A., Croft, M., Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc Natl Acad Sci U S A 103 (2006), 3740–3745.
48. [48] Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A.D., Colombo, M.P., Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105 (2005), 2845–2852.
49. [49] Ruby, C.E., Yates, M.A., Hirschhorn-Cymerman, D., Chlebeck, P., Wolchok, J.D., Houghton, A.N., et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 183 (2009), 4853–4857.
50. [50] Linch, S.N., McNamara, M.J., Redmond, W.L., OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol 5 (2015), 1–14.
51. [51] Curti, B.D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73 (2013), 7189–7198.
52. [52] Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.C., Zitvogel, L., Marabelle, A., Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 52 (2015), 50–66.
53. [53] Vonderheide, R.H., Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 13 (2007), 1083–1088.
54. [54] Van Kooten, C., Banchereau, J., CD40-CD40 ligand. J Leukoc Biol 67 (2000), 2–17.
55. [55] Tutt, A.L., O'Brien, L., Hussain, A., Crowther, G.R., French, R.R., Glennie, M.J., T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168 (2002), 2720–2728.
56. [56] Vonderheide, R.H., Dutcher, J.P., Anderson, J.E., Eckhardt, S.G., Stephans, K.F., Razvillas, B., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19 (2001), 3280–3287.
57. [57] Vonderheide, R.H., Glennie, M.J., Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19 (2013), 1035–1043.
58. [58] Moran, A.E., Kovacsovics-Bankowski, M., Weinberg, A.D., The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25 (2013), 230–237.
59. [59] Wang, L., Rubinstein, R., Lines, J.L., Wasiuk, A., Ahonen, C., Guo, Y., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208 (2011), 577–592.
60. [60] Sakr, M.A., Takino, T., Domoto, T., Nakano, H., Wong, W., Sasaki, M., et al. GI24 enhances tumour invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci 101 (2010), 2368–2374.
61. [61] Lines, J.L., Sempere, L.F., Broughton, T., Wang, L., Noelle, R., VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2 (2014), 510–517.
62. [62] http://investors.curis.com/releasedetail.cfm?releaseid=976471 [Assessed 1 October 2016].
63. [63] Duvic, M., Evans, M., Wang, C., Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol 7 (2016), 171–174.
64. [64] Wilcox, R.A., Mogamulizumab: 2 birds, 1 stone. Blood 125 (2015), 1847–1848.
65. [65] Powerly, J., Cote, G., Flaherty, K., Szmulewitz, R.Z., Ribas, A., Weber, J., et al. Interim results of an ongoing phase 1, dose-escalation study of MGA271 (enoblituzumab), an Fc-optimized humanized anti-B7-H3 monoclonal antibody, in patients with advanced solid cancer. J ImmunoTher Cancer, 3(Suppl. 2), 2015, 8.
66. [66] Ngiow, S.F., Teng, M.W.L., Smyth, M.J., Prospects for TIM-3-targeted antitumour immunotherapy. Cancer Res 71 (2011), 6567–6571.
67. [67] Wherry, E.J., T cell exhaustion. Nat Immunol 12 (2001), 492–499.
68. [68] Woo, S.R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72 (2012), 917–927.
69. [69] Romano, E., Michielin, O., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial. J Transl Med 12 (2014), 97–103.
70. [70] Kim, S., Poursine-Laurent, J., Truscott, S.M., Lybarger, L., Song, Y.J., Yang, L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005), 709–713.
71. [71] Long, E.O., Kim, H.S., Liu, D., Peterson, M.E., Rajagopalan, S., Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31 (2013), 227–258.
72. [72] Aranda, F., Vacchelli, E., Eggemont, A., Galon, J., Fridman, W.H., Zitvogel, L., et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology, 3, 2014 e27297-1-11.
73. [73] Vareki, S.M., Chen, D., Di Cresce, C., Ferguson, P.J., Figueredo, R., Pampillo, M., et al. IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. PloS One, 10, 2015, 10.1371/journal.pone.0143435.
74. [74] Munn, D.H., Mellor, A.L., Indoleamine 2,3-dioxygenase and tumour-induced tolerance. J Clin Invest 117 (2007), 1147–1154.
75. [75] Maleki-Vareki, S., Rytelewski, M., Figueredo, R., Chen, D., Ferguson, P.J., Vincent, M., et al. Indoleamine 2,3-dioxygenase mediates immune-independent human tumour cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 5 (2014), 2778–2791.
76. [76] Vacchelli, E., Aranda, F., Eggermont, A., Sautès-fridman, C., Tartour, E., Kennedy, E.P., et al. Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 3, 2014 e957994-1-10.
77. [77] Soliman, H.H., Minton, S.E., Han, H.S., Ismail-Khan, R., Neuger, A., Khambati, F., et al. A phase I study of indoximod in patients with advanced malignancies. Oncotarget 7 (2016), 22928–22938.
78. [78] Soliman, H.H., Jackson, E., Neuger, T., dees, E.C., Harvey, R.D., Han, H., et al. A first in man phase I trial of the oral immunomodulatory, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5 (2014), 8136–8146.
79. [79] Bahary, N., Garrido-Laguna, I., Cinar, P., O'Rourke, M.A., Somer, B.G., Nyak-Kapoor, A., et al. Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis. J Clin Oncol, 34, 2016 (suppl):abstr 3020.
80. [80] Gibney, G.T., Hamid, O., Gangadhar, T.C., Lutzky, J., Olszanski, A.J., Gajewski, T., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol, 32, 2014 (suppl):abstr 3010.
81. [81] Gainor, J.F., Moving programmed death-1 inhibitors to the front lines in non-small-cell lung cancer. J Clin Oncol 34 (2016), 2953–2955.
82. [82] Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006), 1018–1028.